MRAS
Basic information
Region (hg38): 3:138347648-138405534
Links
Phenotypes
GenCC
Source:
- Noonan syndrome 11 (Strong), mode of inheritance: AD
- Noonan syndrome 11 (Definitive), mode of inheritance: AD
- Noonan syndrome 11 (Moderate), mode of inheritance: AD
- Noonan syndrome 11 (Strong), mode of inheritance: AD
- Noonan syndrome (Supportive), mode of inheritance: AD
- Noonan syndrome 11 (Strong), mode of inheritance: AD
- Noonan syndrome (Moderate), mode of inheritance: AD
Clinical Genomic Database
Source:
Condition | Inheritance | Intervention Categories | Intervention/Rationale | Manifestation Categories | References |
---|---|---|---|---|---|
Noonan syndrome 11 | AD | Cardiovascular | Individuals have been described with cardiac disease, inclduing cardiomyopathy as well as structural cardiac anomalies, and awareness may allow early diagnosis and management (surgical management has been described) | Cardiovascular; Craniofacial; Musculoskeletal; Neurologic | 28289718; 31173466 |
ClinVar
This is a list of variants' phenotypes submitted to
- Noonan syndrome 11 (2 variants)
- RASopathy (1 variants)
Variants pathogenicity by type
Statistics on ClinVar variants can assist in determining whether a specific variant type in the MRAS gene is commonly pathogenic or not.
In the table, we include only reliable ClinVar variants with their consequences to MANE Select, Mane Plus Clinical transcripts, or transcripts with TSL equals 1. Click the count to view the source variants.
Warning: slight differences between displayed counts and the number of variants in ClinVar may occur, primarily due to (1) the application of a different transcript and/or consequence by our variant effect predictor or (2) differences in clinical significance: we classify Benign/Likely benign variants as Likely benign and Pathogenic/Likely pathogenic variants as Likely pathogenic.
Variant type | Pathogenic | Likely pathogenic | VUS | Likely benign | Benign | Sum |
---|---|---|---|---|---|---|
synonymous | 55 | 56 | ||||
missense | 65 | 70 | ||||
nonsense | 1 | |||||
start loss | 0 | |||||
frameshift | 2 | |||||
inframe indel | 1 | |||||
splice donor/acceptor (+/-2bp) | 1 | |||||
splice region | 4 | 11 | 2 | 17 | ||
non coding | 24 | 33 | ||||
Total | 2 | 3 | 71 | 79 | 9 |
Variants in MRAS
This is a list of pathogenic ClinVar variants found in the MRAS region.
You can filter this list by clicking the number of variants in the Variants pathogenicity by type table.
Position | Type | Phenotype | Significance | ClinVar |
---|---|---|---|---|
3-138372859-G-T | Benign (May 04, 2021) | |||
3-138372877-G-A | not specified • MRAS-related disorder | Uncertain significance (Jun 28, 2021) | ||
3-138372895-C-T | Inborn genetic diseases | Likely benign (Jan 29, 2024) | ||
3-138372896-G-A | Uncertain significance (Aug 10, 2023) | |||
3-138372898-C-T | Inborn genetic diseases | Likely benign (Dec 30, 2023) | ||
3-138372899-G-A | Inborn genetic diseases • not specified | Uncertain significance (Jan 03, 2024) | ||
3-138372905-A-G | Inborn genetic diseases | Conflicting classifications of pathogenicity (Oct 28, 2023) | ||
3-138372906-G-C | Uncertain significance (Nov 08, 2023) | |||
3-138372910-C-A | Uncertain significance (Jul 09, 2022) | |||
3-138372912-A-G | Inborn genetic diseases | Uncertain significance (Oct 08, 2023) | ||
3-138372913-C-T | Likely benign (Feb 22, 2023) | |||
3-138372915-T-C | Uncertain significance (Jun 03, 2022) | |||
3-138372919-C-T | Likely benign (Jul 07, 2023) | |||
3-138372921-C-T | Uncertain significance (Jul 25, 2023) | |||
3-138372922-A-G | Likely benign (Jul 06, 2022) | |||
3-138372925-C-T | Inborn genetic diseases | Likely benign (Jan 03, 2024) | ||
3-138372928-G-A | Inborn genetic diseases | Likely benign (Jan 20, 2023) | ||
3-138372940-G-A | Likely benign (Nov 09, 2021) | |||
3-138372949-G-T | Inborn genetic diseases | Benign/Likely benign (Jan 05, 2024) | ||
3-138372950-G-C | RASopathy | Likely pathogenic (Sep 17, 2024) | ||
3-138372951-G-T | Noonan syndrome 11 • RASopathy | Likely pathogenic (Sep 17, 2024) | ||
3-138372963-G-C | Inborn genetic diseases | Uncertain significance (Jan 14, 2020) | ||
3-138372967-C-A | Likely benign (Dec 17, 2022) | |||
3-138372968-C-T | Uncertain significance (Oct 13, 2022) | |||
3-138372997-T-C | Inborn genetic diseases | Likely benign (May 06, 2024) |
GnomAD
Source:
Gene | Type | Bio Type | Transcript | Coding Exons | Length |
---|---|---|---|---|---|
MRAS | protein_coding | protein_coding | ENST00000289104 | 5 | 57837 |
pLI Probability LOF Intolerant | pRec Probability LOF Recessive | Individuals with no LOFs | Individuals with Homozygous LOFs | Individuals with Heterozygous LOFs | Defined | p |
---|---|---|---|---|---|---|
0.921 | 0.0785 | 125714 | 0 | 8 | 125722 | 0.0000318 |
Z-Score | Observed | Expected | Observed/Expected | Mutation Rate | Total Possible in Transcript | |
---|---|---|---|---|---|---|
Missense | 2.33 | 56 | 131 | 0.428 | 0.00000816 | 1393 |
Missense in Polyphen | 12 | 56.376 | 0.21286 | 612 | ||
Synonymous | 0.594 | 46 | 51.4 | 0.895 | 0.00000347 | 375 |
Loss of Function | 2.64 | 0 | 8.14 | 0.00 | 3.42e-7 | 109 |
LoF frequencies by population
Ethnicity | Sum of pLOFs | p |
---|---|---|
African & African-American | 0.000246 | 0.000246 |
Ashkenazi Jewish | 0.00 | 0.00 |
East Asian | 0.00 | 0.00 |
Finnish | 0.00 | 0.00 |
European (Non-Finnish) | 0.0000275 | 0.0000264 |
Middle Eastern | 0.00 | 0.00 |
South Asian | 0.00 | 0.00 |
Other | 0.000163 | 0.000163 |
dbNSFP
Source:
- Function
- FUNCTION: May serve as an important signal transducer for a novel upstream stimuli in controlling cell proliferation. Weakly activates the MAP kinase pathway. {ECO:0000269|PubMed:16630891}.;
- Pathway
- Autophagy - animal - Homo sapiens (human);HTLV-I infection - Homo sapiens (human);Regulation of actin cytoskeleton - Homo sapiens (human);Mitophagy - animal - Homo sapiens (human);Apelin signaling pathway - Homo sapiens (human);C-type lectin receptor signaling pathway - Homo sapiens (human);Rap1 signaling pathway - Homo sapiens (human);Ras signaling pathway - Homo sapiens (human);MAPK signaling pathway - Homo sapiens (human);Phospholipase D signaling pathway - Homo sapiens (human);Proteoglycans in cancer - Homo sapiens (human);Cellular senescence - Homo sapiens (human);EGFR Inhibitor Pathway, Pharmacodynamics;Bisphosphonate Pathway, Pharmacodynamics;Vemurafenib Pathway, Pharmacodynamics;update your name in edit mode;MAPK Signaling Pathway;Ras Signaling;Regulation of Actin Cytoskeleton
(Consensus)
Recessive Scores
- pRec
- 0.178
Intolerance Scores
- loftool
- rvis_EVS
- -0.14
- rvis_percentile_EVS
- 42.88
Haploinsufficiency Scores
- pHI
- 0.267
- hipred
- Y
- hipred_score
- 0.825
- ghis
- 0.597
Essentials
- essential_gene_CRISPR
- N
- essential_gene_CRISPR2
- N
- essential_gene_gene_trap
- N
- gene_indispensability_pred
- E
- gene_indispensability_score
- 0.902
Gene Damage Prediction
All | Recessive | Dominant | |
---|---|---|---|
Mendelian | Medium | Medium | Medium |
Primary Immunodeficiency | Medium | Medium | Medium |
Cancer | Medium | Medium | Medium |
Mouse Genome Informatics
- Gene name
- Mras
- Phenotype
- hematopoietic system phenotype; normal phenotype; immune system phenotype;
Gene ontology
- Biological process
- Ras protein signal transduction;multicellular organism development;muscle organ development;actin cytoskeleton organization;cellular response to leukemia inhibitory factor
- Cellular component
- plasma membrane
- Molecular function
- GTPase activity;protein binding;GTP binding;GTP-dependent protein binding